ATAI Life Sciences NV

ATAI remains in a Stage 2 advancing structure with a strong long-term uptrend, but price is extended above rising EMAs in an extreme overbought context without Lockout Rally support. Short-term timing is neutral, so speculative entries are deferred until a shallow pullback into the 9 EMA/21 EMA offers an asymmetric setup.

• ↑Cash reserves of $430M extend runway into 2024 for 11 programs
• ↑Phase IIb dosing for VLS-01 done; topline data due Q4 2026
• ↓Extremely negative earnings yield and low book-to-price imply overvaluation